Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has revealed that it will introduce its Nektar co-developed inhaled diabetes drug Exubera in September, several weeks later than initially planned.
Subscribe to our email newsletter
The delay is due to the fact that Pfizer wants to introduce Exubera after conducting a comprehensive physician and patient education and training program. To further support patients and healthcare professionals in the treatment of diabetes and appropriate use of Exubera, Pfizer is also providing a 24-hour, seven-day call center staffed by healthcare professionals.
Karen Katen, vice chairman of Pfizer and president of Pfizer Human Health, acknowledged that their education programs and manufacturing preparations are time-consuming but commented, “we are taking the time necessary to do the job right.”
Exubera represents one of the most significant innovations in insulin delivery since the introduction of insulin 85 years ago. The drug offers patients a novel method of introducing insulin into their systems via the lungs and long-term efficacy and safety data in both type 1 and type 2 diabetes suggest that Exubera could lead to better blood glucose control.
Nektar also announced that it is updating its 2006 revenue guidance. The company is increasing its revenue guidance for Exubera manufacturing and royalty revenue from a range of $60 to $80 million to a range of $70 to $90 million, with most of the revenue being generated by manufacturing sales to Pfizer.